Tags

Type your tag names separated by a space and hit enter

Current immunotherapy in rheumatoid arthritis.
Immunotherapy 2013; 5(9):955-74I

Abstract

Rheumatoid arthritis is a common autoimmune disease primarily manifesting as chronic synovitis, subsequently leading to a change in joint integrity. Progressive disability and systemic complications are strongly associated with a decreased quality of life. To maintain function and health in patients with rheumatoid arthritis, early, aggressive and guided immunosuppressive therapy is required to induce clinical remission. Antirheumatic drugs are capable of controlling synovial inflammation and are therefore named 'disease-modifying antirheumatic drugs' (DMARDs). This article aims to bridge the beginning of DMARD therapy with agents such as methotrexate, leflunomide, sulfasalazine, injectable gold and (hydroxy)chloroquine with biological therapies, and with the new era of kinase inhibitors. Mechanisms of action, as well as advantages and disadvantages of DMARDs, are discussed with respect to the current literature and current recommendations.

Authors+Show Affiliations

Department of Internal Medicine & Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23998731

Citation

Meier, Florian M P., et al. "Current Immunotherapy in Rheumatoid Arthritis." Immunotherapy, vol. 5, no. 9, 2013, pp. 955-74.
Meier FM, Frerix M, Hermann W, et al. Current immunotherapy in rheumatoid arthritis. Immunotherapy. 2013;5(9):955-74.
Meier, F. M., Frerix, M., Hermann, W., & Müller-Ladner, U. (2013). Current immunotherapy in rheumatoid arthritis. Immunotherapy, 5(9), pp. 955-74. doi:10.2217/imt.13.94.
Meier FM, et al. Current Immunotherapy in Rheumatoid Arthritis. Immunotherapy. 2013;5(9):955-74. PubMed PMID: 23998731.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current immunotherapy in rheumatoid arthritis. AU - Meier,Florian M P, AU - Frerix,Marc, AU - Hermann,Walter, AU - Müller-Ladner,Ulf, PY - 2013/9/4/entrez PY - 2013/9/4/pubmed PY - 2014/3/29/medline SP - 955 EP - 74 JF - Immunotherapy JO - Immunotherapy VL - 5 IS - 9 N2 - Rheumatoid arthritis is a common autoimmune disease primarily manifesting as chronic synovitis, subsequently leading to a change in joint integrity. Progressive disability and systemic complications are strongly associated with a decreased quality of life. To maintain function and health in patients with rheumatoid arthritis, early, aggressive and guided immunosuppressive therapy is required to induce clinical remission. Antirheumatic drugs are capable of controlling synovial inflammation and are therefore named 'disease-modifying antirheumatic drugs' (DMARDs). This article aims to bridge the beginning of DMARD therapy with agents such as methotrexate, leflunomide, sulfasalazine, injectable gold and (hydroxy)chloroquine with biological therapies, and with the new era of kinase inhibitors. Mechanisms of action, as well as advantages and disadvantages of DMARDs, are discussed with respect to the current literature and current recommendations. SN - 1750-7448 UR - https://www.unboundmedicine.com/medline/citation/23998731/Current_immunotherapy_in_rheumatoid_arthritis_ L2 - http://www.futuremedicine.com/doi/full/10.2217/imt.13.94?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -